-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-501374-19-00
4
2022-09-16
Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chr
-
2024-514617-35-00
4
2021-12-20
Progressive forms of Multiple Sclerosis
-
2023-506688-32-00
5
2019-10-09
Primary Generalized Tonic-Clonic Seizures
-
2025-523757-33-00
4
2026-05-07
multiple sclerosis
-
2025-523557-33-00
4
2026-04-20
Moderate-to-Severe Hidradenitis Suppurativa
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-522029-37-00
5
2026-02-27
Large B-cell Lymphoma
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2023-508935-30-00
5
2025-11-20
Lower extremity artery disease
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2024-520156-22-00
4
2025-10-08
Metastatic hormone-sensitive prostate cancer
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-519284-18-00
5
2025-06-18
Relapsing multiple sclerosis
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer